Literature DB >> 2435930

Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines.

W S Hong, J R Jett, Y Sasaki, H Takahashi, H Nakano, K Nakagawa, A Hoshi, N Saijo.   

Abstract

This study was conducted to assess, by continuous exposure, the inhibitory effects of rH-TNF and rH-IFN-alpha, -beta and -gamma, either alone or in combination, on the colony formations of human lung cancer cell lines. The cell lines tested were PC-7 and PC-9 (adenocarcinoma), PC-10 (squamous cell carcinoma) and PC-13 (large cell carcinoma). Additional experiments were performed with L929 (transformed murine fibroblast), because of its known high sensitivity to TNF. rH-TNF inhibited the colony formations of PC-10 and L929 even at a low concentration (10 U/ml). However, PC-7, PC-9 and PC-13 were resistant to rH-TNF. rH-IFN-alpha, -beta and -gamma inhibited the colony formation of PC-10 (less than 50% of control) at the highest concentration tested (10(4) U/ml), but only rH-IFN-beta inhibited that of PC-7. PC-9, PC-13 and L929 were insensitive to all three rH-IFNs, even at the highest concentrations tested. Combination effects of rH-TNF and rH-IFN-alpha or -gamma were synergistic only at the highest concentration combinations tested in PC-9. However, the maximum inhibition of colony formation of PC-7, PC-9 or PC-13 in any concentration combination treatment was less than 50%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2435930

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Down modulation of IFN-gamma signaling in alveolar macrophages isolated from smokers.

Authors:  Navneet K Dhillon; William J Murphy; Michael B Filla; Ana J Crespo; Heath A Latham; Amy O'Brien-Ladner
Journal:  Toxicol Appl Pharmacol       Date:  2009-03-06       Impact factor: 4.219

2.  An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.

Authors:  J H Schiller; D Neuberg; D Burns; P Ritch; M Larson; M Levitt; J Dutcher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians.

Authors:  Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Yun-Ling Zheng; Zhipeng Yu; Glenwood Trivers; Anthony J Alberg; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

4.  Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.

Authors:  L Boldrini; A Calcinai; E Samaritani; F Pistolesi; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Fontanini
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

5.  Construction and in vivo/in vitro evaluation of a nanoporous ion-responsive targeted drug delivery system for recombinant human interferon α-2b delivery.

Authors:  Hongfei Liu; Jie Zhu; Pengyue Bao; Yueping Ding; Yan Shen; Thomas J Webster; Ying Xu
Journal:  Int J Nanomedicine       Date:  2019-07-16

6.  Enhancement of cytotoxicity of cisplatin in vitro by recombinant human tumor necrosis factor and/or recombinant human interferon-alpha, -beta and -gamma.

Authors:  C M Kim; W S Hong; J O Lee; T W Kang; Y W Kim; J K Song; T K Yun; C Y Kim
Journal:  Jpn J Cancer Res       Date:  1989-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.